Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

RPT-U.S. Senate panel to debate wave of corporate tax-avoidance deals

Tue, 22nd Jul 2014 05:00

(Repeats story published late on Monday)

By Kevin Drawbaugh

WASHINGTON, July 21 (Reuters) - As more U.S. corporations dodeals to cut taxes by shifting their tax domiciles overseas, theSenate Finance Committee will hold a hearing on Tuesday focusedon these transactions known as inversions.

Nine such deals have been agreed to this year by companiesranging from banana distributor Chiquita Brands International,Inc to drugmaker AbbVie Inc and more are beingconsidered. The transactions are setting a record pace since thefirst inversion was done 32 years ago.

Witnesses at the Senate Finance Committee's hearing willinclude government officials and academics. Chairman Ron Wyden,a Democrat from Oregon, is expected to call for stand-alonelegislation to respond to the flurry of inversions that hasWashington on edge.

Democrats, searching for campaign issues before November'scongressional elections, have jumped on inversions, and severalof them have offered bills that would curb the deals.

But no new law is likely to result as long as Republicanscontend that inversion rules need to be part of a broaderoverhaul of the tax code, policy analysts said.

The Republican-controlled U.S. House of Representatives willnot act on inversions "unless there's comprehensive tax reform,and that's dead for this year," said Greg Valliere, chiefpolitical strategist at Potomac Research Group in a client noteon Monday.

Inversions are still rare, but they are becoming morecommon. Of the roughly 60 deals done since 1982, more than halfhave come in just the last six years, a Reuters review showed.

An inversion involves a U.S. corporation buying or settingup a smaller company abroad, then shifting its tax home base tothat company's country, which typically has lower tax rates thanin the United States.

Such deals seldom mean a U.S. corporation physically leaveshome. Usually an inversion means that a company will open asmall office abroad, perhaps in England or Ireland, as a newaddress for tax purposes, leaving major operations intact.

But the move can put foreign earnings out of the reach ofthe Internal Revenue Service and make other tax savings possiblethat can boost a multinational company's bottom line.

U.S. Treasury Secretary Jacob Lew urged Congress last weekto take steps quickly to discourage inversions.

In a letter to members of Congress, he said corporationsthat do inversions want to keep U.S. advantages - such as intellectual property protection, research support, financialsecurity and reliable infrastructure - without paying for them.

President Barack Obama's 2015 budget proposed makinginversions harder to do by raising the foreign ownershiprequired. Congressional Democrats have made similar proposals.

Drugstore chain Walgreen Co is weighing a possibleinversion. Drugmaker Pfizer Inc's bid in April to buy UKrival AstraZeneca Plc was structured as an inversion.That deal collapsed, but it drew attention to the issue. (Editing by Jan Paschal)

More News
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.